The pharmaceutical industry is in the midst of a "perfect storm." The traditional blockbuster approach is yielding diminishing returns while post-genomic research is driving towards personalized medicine. The result is an inflection point, where the emphasis on blockbusters and traditional mass-marketing is being challenged by the new paradigm of personalized medicine.
Targeted therapies, based upon genotype, require a new brand model that addresses smaller segments of the population. This model, according to Francoise Simon, professor of marketing at the Columbia University Graduate School of Business, requires a fundamental reorganization of the biopharma value chain, from discovery to manufacturing and marketing. She was speaking at a recent World Congress on Pharmaceutical Marketing held in Philadelphia, PA.
- At an Inflection Point
- Biologics are Big Business
- Evidence-Based Marketing
- Lamisil: A Case Study
- Absolute Shift to Personalized Medicine Unlikely
- Possible Future Scenarios